Contact
Please use this form to send email to PR contact of this press release:
BeiGene Announces First Patient Dosing in China with Investigational PARP Inhibitor BGB-290
TO:
Please use this form to send email to PR contact of this press release:
BeiGene Announces First Patient Dosing in China with Investigational PARP Inhibitor BGB-290
TO: